• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Agenus Inc. - Common Stock (NQ:AGEN)

    3.680 -1.000 (-21.37%)
    Streaming Delayed Price Updated: 4:00 PM EST, Jan 15, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 3,180,032
    Open 4.690
    Bid (Size) 3.730 (100)
    Ask (Size) 3.800 (100)
    Prev. Close 4.680
    Today's Range 3.610 - 4.830
    52wk Range 1.380 - 7.340
    Shares Outstanding 348,875,959
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Thursday's session: top gainers and losers ↗
    Via Chartmill
    Which stocks are moving on Thursday? ↗
    Via Chartmill

    Performance

    YTD
    +13.9%
    +13.9%
    1 Month
    -1.1%
    -1.1%
    3 Month
    -7.8%
    -7.8%
    6 Month
    -45.2%
    -45.2%
    1 Year
    +16.1%
    +16.1%

    More News

    Read More
    These stocks are gapping in today's session ↗
    Via Chartmill
    News headline image
    Agenus Announces Closing of $141M Strategic Collaboration with Zydus Lifesciences to Advance BOT+BAL and Strengthen U.S. Manufacturing Readiness
    From Agenus Inc.
    Via Business Wire
    News headline image
    Earnings Scheduled For November 10, 2025 ↗
    Via Benzinga
    News headline image
    France Expands National AAC Access for Agenus' Botensilimab + Balstilimab for Ovarian Cancer and Soft-Tissue Sarcomas
    From Agenus Inc.
    Via Business Wire
    News headline image
    Agenus (AGEN) Q3 2024 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    Agenus (AGEN) Q1 2025 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    Agenus (AGEN) Q4 2024 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    Agenus Reports Deep, Durable Responses with Botensilimab + Balstilimab in Highly Refractory Ovarian Cancer, Published in JITC
    From Agenus Inc.
    Via Business Wire
    News headline image
    Agenus to Host End-of-Year Stakeholder Webcast Featuring GI Oncology Leaders and Progress of BOT/BAL
    From Agenus Inc.
    Via Business Wire
    News headline image
    GI Cancer Immunotherapy Breakthroughs Signal New Treatment Era
    From Equity Insider
    Via GlobeNewswire
    News headline image
    Agenus Appoints Dr. José Iglesias as Chief Medical Affairs Officer to Guide Global Medical Affairs and Early-Access Programs, Including France’s AAC
    From Agenus Inc.
    Via Business Wire
    News headline image
    AGENUS INC (NASDAQ:AGEN) Reports Mixed Q3 2025 Earnings, Driven by One-Time Gain ↗
    Via Chartmill
    News headline image
    Agenus Reports Q3 2025 Results Showcasing Clinical and Regulatory Advances
    From Agenus Inc.
    Via Business Wire
    News headline image
    Insights Ahead: Agenus's Quarterly Earnings ↗
    Via Benzinga
    News headline image
    Ligand Pharmaceuticals Soars to New Heights: A Deep Dive into its 52-Week High
    Via MarketMinute
    Topics Intellectual Property
    News headline image
    Agenus to Provide Corporate Update and Third Quarter 2025 Financial Report
    From Agenus Inc.
    Via Business Wire
    News headline image
    Agenus Reports 39% of Patients Alive at Two-Years with BOT/BAL Across Multiple Refractory Solid Tumors at ESMO 2025
    From Agenus Inc.
    Via Business Wire
    News headline image
    Agenus to Host October Stakeholder Briefing Showcasing BOT/BAL Global Momentum and Post-ESMO Insights
    From Agenus Inc.
    Via Business Wire
    News headline image
    France Grants Reimbursed Compassionate Access (AAC) for Agenus’ BOT/BAL in Refractory MSS Metastatic Colorectal Cancer
    From Agenus Inc.
    Via Business Wire
    News headline image
    Agenus to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
    From Agenus, Inc.
    Via Business Wire
    News headline image
    Update: Agenus Aug 27 Stakeholder Webcast—Transformative IO Updates, BOT/BAL Data, BATTMAN Preview, Zydus Partnership Momentum, and MiNK Spotlight
    From Agenus Inc.
    Via Business Wire
    News headline image
    Agenus to Unveil BOT/BAL Strategic Advancements, Key Milestones, and Future Outlook in Virtual Stakeholder Briefing on August 27, 2025
    From Agenus Inc.
    Via Business Wire
    News headline image
    Monday's pre-market session: top gainers and losers ↗
    Via Chartmill

    Frequently Asked Questions

    Is Agenus Inc. - Common Stock publicly traded?
    Yes, Agenus Inc. - Common Stock is publicly traded.
    What exchange does Agenus Inc. - Common Stock trade on?
    Agenus Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Agenus Inc. - Common Stock?
    The ticker symbol for Agenus Inc. - Common Stock is AGEN on the Nasdaq Stock Market
    What is the current price of Agenus Inc. - Common Stock?
    The current price of Agenus Inc. - Common Stock is 3.680
    When was Agenus Inc. - Common Stock last traded?
    The last trade of Agenus Inc. - Common Stock was at 01/15/26 04:00 PM ET
    What is the market capitalization of Agenus Inc. - Common Stock?
    The market capitalization of Agenus Inc. - Common Stock is 1.28B
    How many shares of Agenus Inc. - Common Stock are outstanding?
    Agenus Inc. - Common Stock has 1B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.